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Conjugated linoleic acids (CLAs) are positional and geometrical isomers of linoleic acid and some 
researchers have shown biological activities including modulation of lipid metabolism, atherogenesis, 
diabetes, and immune functions. In this study, the animals were supplemented with 2% of the average 
feed consumption with CLA (G1 = positive control) and safflower oil (G2 = negative control) and the test 
groups were supplemented with CLA at the concentration of 2 and 4% of the average feed 
consumption. To assess the CLA potential protective effect, two groups were used; G3 = CLA 2% + 
cyclophosphamide (CP) and G5 = CLA 4% + CP. To assess the mutagenic effects of CLA, two groups 
were used; G4 = CLA 2% + NaCl 0.9% and G6 = CLA 4% + NaCl 0.9%. In order to investigate the 
mutagenic/antimutagenic effects of CLA, micronucleus test was used. The results showed variation of 
feed consumption in the groups that received 4% of CLA, when compared to the control group (G1 and 
G2) and  CLA  groups (G3 and G4) (p<0.05), during the period studied. It was observed that CLA did not 
show mutagenic effect at the concentrations tested (2 and 4%). Also, CLA showed antimutagenic effect 
at the same concentrations. However, the animals that received 4% of CLA, presented clinical signs of 
malnutrition.  
 





Conjugated linoleic acid (CLA) is a dietary adjuvant for its 
anticarcinogenic properties and other biological activities 
such as modulation of lipid metabolism, atherogenesis, 
diabetes, hypertension, asthma and immune functions 
(Degner et al., 2006; DeClercq et al., 2011; Ing and 
Belury, 2011; MacRedmond and Dorscheid, 2011). 
Conjugated linoleic acid (CLA) is a general term 
referring to a mixture of geometrical and position isomers 
of the octadecadienoic acid and is found in food derived 
from ruminants such as beef and lamb, as well as the 
dairy products from these sources (Lee et al., 1994). 
Most of the published studies have used a mixture of 
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(c9, t11-CLA) and trans-10, cis-12-CLA, (t10, c12-CLA), 
and a number of minor isomers (t7, t9-CLA; c9, c11-CLA; 
t9, t11-CLA;c10, c12-CLA; t10, t12-CLA; t11, t13-CLA; 
and c11, c13-CLA) (Kelley, 2007; DeClercq et al., 2011; 
Guler and Aktumsek, 2011). 
The first investigation of the possible health promoting 
properties of CLA was published by Pariza et al. (1979), 
who found unidentified anticarcinogenic factors in fried 
ground beef. Ground beef extract contained anti-
mutagenic compounds that selectively inhibited rat liver 
S-9-mediated mutagenesis (Pariza et al., 1979; Pariza, 
1983). In a subsequent study, a factor that inhibited the 
initiation of mouse epidermal carcinogenesis induced by 
7, 12-dimethylbenz[a]anthracene (DMBA) was found in 
grilled ground beef (Pariza and Hargraves, 1985). The 
factor was isolated and identified as an isomeric mixture 






Among the several tests of assessment of carcinogenic 
compounds, the rodent bone marrow micronucleus test is 
largely investigated and could be referred to as a 
cytogenetic method based on counts  of  micronucleus  in  
the cytoplasm of newly formed cell (Hayashi et al., 1994). 
Evaluation of micronucleus frequency in vivo is the 
primary test in a battery of genotoxicity tests and is 
recommended by the regulatory agencies worldwide the 
globe to be conducted as part of product safety 
assessment (Krishna and Hayashi, 2000). Micronucleus 
test has many advantages: reliable identification of cells 
that have completed only one nuclear division, sensitivity 
and precision, quickness and simplicity, the ability to 
screen large numbers of cells, and good reproducibility.  
Micronucleus which appear in the cytoplasm of the 
divided cells as small additional nuclei result from 
chromosome fragments or whole chromosomes that are 
left behind during mitotic division. 
Thus, the presence of micronucleus is an indication of 
exposure to clastogenic and/or aneugenic agents 
(Ramírez, 1999). 
Thus, after determining the fatty acid profile of the CLA 
and placebo (safflower oil), the objective of this study was 
to evaluate the effects of mutagenic and antimutagenic 
effects of conjugated linoleic acid on bone-marrow cell of 
mice through micronucleus test. 
 
 




Supplements used were commercial conjugated linoleic acid 
Tonalin® TG 80 and safflower oil (oil arising from the seed of 
Carthamus tinctorius L.), both from Cognis Brazil Limited. 
 
 
Determination of the fatty acid profile of the CLA and placebo 
(safflower oil) 
 
The methylation of fatty acids was performed using the method 
described by Christie (1982). For determination of the fatty acid 
profile, a gas chromatograph equipped with fused silica capillary 
columns, CP SIL 88 (0.25 mm x 0.2 µm x 100 m) and flame 
ionization detector (FID) was used. A temperature gradient was 
used, in which the first temperature was 70°C for 4 min, and then, 
an increase of 13°C per min until 175°C (maintained for 27 min) 
was performed, followed by an increase of 4°C per min until 215°C 
for 11 min, and followed again by an increase of 4°C until 240°C 
during 4 min; total of 70 min for the run. The temperatures of 
injector and detector were 250 and 300°C respectively. The 
injection mode was split, with 50:1 ratio. Carrier gas was hydrogen 




Animals and diets 
 
For biological assays, three weeks old male Swiss mice (25±5 g) 
were obtained from Central Animal Facility of the Federal University 
of Alfenas. The animals were housed in wire topped opaque 
polycarbonate cages and maintained under constant environmental 
conditions   on   a   12 h  light/dark   schedule.   The   environmental  




temperature was 20 ± 2°C and 50% humidity. Commercial feed and 
water were provided ad libitum. All experiments were conducted 
according to Brazilian regulations for animal experimentation 
(COBEA),   after   approval   by   the  Ethics  Committee  on  Animal  






The 36 Swiss albino male mice were distributed in six groups with 
six animals each, according to the following distribution: G1 
(positive control) = safflower 2% + cyclophosphamide (CP); G2 
(negative control) = safflower 2% + NaCl 0.9%; G3 (experimental 
group) = CLA 2% + CP; G4 (experimental group) = CLA 2% + NaCl 
0.9%; G5 (experimental group) = CLA 4% + CP; G6 (experimental 
group) = CLA 4% + NaCl 0.9%. To assess the CLA potential 
protective effect, two groups were used; G3 and G5. To assess the 
mutagenic effects of CLA, two groups were used; G4 and G6. 
Throughout the experimental period, animals were supplemented 
by orogastric gavage with disposable syringe of 1ml (Figure 1). 
Cyclophosphamide (50 mg/kg body weight) was injected in three 
groups (G1, G3 and G5) 24 h before the euthanasia and the other 
three groups received NaCl 0.9% (G2, G4 and G6). Both femur 
bones were excised and their bone marrow flushed into test tubes 
using a syringe containing bovine fetal serum. All animals were 
sacrificed 24 h after treatment by cervical dislocations under ether 





Animals were supplemented by orogastric gavage with 1 ml 
disposable syringes and gavage needles. The amount of 
supplement was calculated every other day, based on the average 
feed consumption of each group, so that supplementation followed 
normal feed ingestion. Supplements were aspirated with the syringe 
and kept away from light until the moment of administration. Mice 
were removed group by group from the experiment room, placed in 
plastic boxes, and taken to the supplementation room. This 
procedure was done daily during daytime and always at the same 
time, since rodents have nocturnal habits.  
 
 
Sampling preparation for micronucleus test 
 
For the conventional assessment of micronucleus frequencies, two 
slides for each animal were prepared according to the method 
described by MacGregor et al. (1987). Briefly, femurs were 
dissected, cleaned of any adhering muscle and bone marrow cells 
were flushed with bovine fetal serum into a centrifuge tube. The 
cells were stained with Leishmann and centrifuged at 2000 rpm for 
5 min and supernatant was removed. The slides were coded, and 
the cells blindly scored by light microscope at 1000X magnification. 
The frequency of micronucleated polychromatic erythrocytes 
(MNPCE) in each mouse was used as the experimental unit, with 
variability (standard deviation) based on differences among animals 
within the same group. Polychromatic erythrocytes/normochromatic 
erythrocytes (PCE/NCE) ratio was also determined as a total of 





Statistical analysis was performed using the Sisvar package® 
(Ferreira, 2004). The frequencies of MNPCE between treatment 
groups and their respective controls were compared by the chi-
square test (χ2). The results were considered statistically significant  











if the p values obtained were less than 0.05. Evaluations of mean 
body weight and diet consumption, were performed using one-way 
analysis of variance  (ANOVA/Tukey,  p<0.05).   
The  percentage  of reduction in the frequency of 
cyclophosphamide-induced DNA damage was calculated as 
follows: 
 
(Mean frequency of damage in A) - (mean frequency of damage in 
B) % reduction =  x 100 
                                                                                        
(Mean frequency of damage in A) - (mean frequency of damage in 
C) 
 
Where, A = positive control group treated with CP, B = group 
treated with the CLA + CP and C = negative control group.  
 
 
RESULTS AND DISCUSSION 
 
Determination of the fatty acid profile of the CLA and 
placebo (safflower oil) 
 
Table 1 provides the composition of fatty acid from 
safflower oil supplement and mixture of CLA isomers. 
The amount of linoleic acid and CLA isomers was 77.75 




Animals and diets 
 
During the experiment, the animals were weighed and 
the consumption of ration was controlled. These results 
are shown in Table 2, which shows the  variation of 
weight gain and feed consumption in the groups that 
received 2 and 4% of CLA when compared to the control 
group (p<0.05), during the period studied.  
The frequency of micronucleus (MN) in MNPCE of mice 
bone marrow, was lower (p<0.05) after administration of 
the substances tested (2 and 4% of CLA), as presented 
in Table 3. 
According to profile of fatty acid indicated on Table 1, 
the safflower oil supplement used for orogastric gavage 
by control group contained 77.75 g of linoleic acids per 
100 g of total fatty acids. The supplement of conjugated 
linoleic acid used for orogastric gavage by the test groups  










Conjugated linoleic acid  
Tonalin® (g/100 g) 
C4:0 - - 
C6:0 0.004 - 
C8:0 0.025 - 
C10:0 0.021 0.029 
C10:1 - - 
C11:0 - - 
C12:0 0.037 0.032 
C12:1 - - 
C13:0 - 0.227 
C13:0 isso - - 
C13:0 anteiso - - 
C14:0 0.146 - 
C14:0 isso - - 
C14:1 cis-9 - - 
C15:0 - - 
C15:0 isso 0.005 - 
C15:0 anteiso - - 
C15:1 - - 
C16:0 6.347 2.733 
C16:0 isso - - 
C16:1 cis-9 0.086 - 
C17:0 0.029 0.035 
C17:0 isso - - 
C17:1 0.024 - 
C18:0 2.191 2.767 
C18:1 trans-6 - - 
C18:1 trans-10 - - 
C18:1 trans-16 0.068 0.24 
C18:1 cis-9 12.147 10.148 
C18:1 cis-11 0.528 1.511 
C18:1 cis-12 0.239 0.787 
C18:1 cis-13 0.1 0.474 
C18:1 cis-15 - - 
C18:2 trans-11. cis-15 - - 
C18:2 cis-9. cis-12 77.757 - 
C18:2 cis-9. trans-11 CLA - 38.426 
C18:2 trans-10. cis-12 CLA - 41.592 
C:18:3 0.059 - 
C20:1 - - 
C20:3 - - 
C20:4 - - 
C20:5 - - 
C22:0 - - 
C22:1 - - 
C22:5 - - 
C22:6 - - 
C24:0 - - 
C24:1 - - 
Total 
99.948 99.142 











Total feed consumption (g) 
Initial Final 
G1 28.21±3.76Aa 32.35±3.90Aa 98.42±4.33A 
G2 24.81±2.99Aa 27.35±4.65ABa 92.44±3.11A 
G3 26.96±0.53Aa 21.05±4.39Ba 83.50±4.72B 
G4 26.46±2.46Aa 22.39±3.37Ba 81.66±3.93B 
G5 26.42±2.35Aa 21.55±2.07Bb 51.77±5.95C 
G6 27.46±1.30Aa 21.17±1.17 Bb 60.97±6.42C 
 
*G1 (positive control) = safflower 2% + CP; G2 (negative control) = safflower 2% + NaCl; G3 = CLA 2% + CP; G4 = CLA 2% 
+ NaCl; G5 = CLA 4% + CP; G6 = CLA 4% + NaCl. ‡ Values sharing similar capital letter in the same column and minuscule 




Table 3. Frequency of MNPCEs of bone marrow of mice Swiss of the experimental groups treated with 




Nº % % of reduction 
G1 122 2.03 
 
G2 20 0.33 
 
G3 17 0.43 94.60 
G4 18 0.45 
 
G5 40 1.00 60.78 
G6 21 0.53  
 
*G1 (positive control) = safflower 2% + CP; G2 (negative control) = safflower 2% + NaCl; G3 = CLA 2% + CP; G4 = 




contained a mixture of CLA isomers. The major CLA 
isomers (cis-9, trans-11 and trans-10, cis-12) were 
present at the ratio of 1:1, approximately.  
Among the other CLA isomers, cis-9, trans-11 and 
trans-12, and cis-12 are regarded as biological active. 
Isomers cis-9 and trans-11 showed anti-carcinogenic 
effects (Ip et al., 1999), and isomers trans-10, and cis-12 
are particularly involved in the change of body com-
position (Park et al., 1999). 
It is very difficult and expensive to isolate each of these 
isomers; this is the reason why most of the studies with 
CLA have used commercial mixture made from vegetable 
oil with predominantly CLA isomers cis-9, trans-11and 
trans-10, and cis-12 at the ratio of 1:1 (Funck et al., 
2007). Therefore, it is not possible to award results for 
each isomer in isolated form.  
The results of weight gain and food consumption 
suggest that the consumption of CLA at different 
concentrations interferes with animal development, 
growth and food intake. These effects appear to correlate 
with a control of the satiety-related factors such as leptin, 
ghrelin, adiponectin and resistin. Leptin is a hormone 
synthesized and secreted by adipocytes in the plasma, 
while ghrelin is secreted from the gastrointestinal tract. 
Adiponectin and resistin are adipokines secreted by 
preadipocytes and mature adipocytes, respectively 
(Hermsdorff and Monteiro, 2004; Romero and Zanesco, 
2006). Supplementation with 2% of CLA on food intake 
was able to reduce leptin levels in rats (Botelho et al., 
2008). In addition, CLA supplementation was able to 
inhibit the activity of the activated peroxisome proliferator-
activated receptors γ (γ PPAAR) and this in turn reduced 
the expression of genes for leptin in rodents and 
adipocytes (Zhang et al., 1996; Ing and Belury, 2011). 
The t10,c12-CLA isomer attenuates development of 
obesity-related hypertension, at least in part, by stimu-
lating adiponectin production, which subsequently 
activates vascular endothelial nitric oxide synthase 
(DeClercq et al., 2011). 
In studies with Wistar rats, Botelho et al. (2005) 
evaluated the effect of dietary CLA at concentrations of 1, 
2 and 3% of its daily diet. When compared with the 
control (linoleic acid 2%), animals that received 1% of 
CLA showed less weight loss. In the animals that 
received 2 and 4% of CLA, there was reduction on fat 
mass content. In this study, consumption of CLA 
influenced the feed intake and consequently the weight 





compared to the control groups and 2% CLA.  
With the aim to investigate the potential mutagenic/ 
antimutagenic effects, this research adopted the 2 and 
4% of CLA, due to the results of fat loss found by Botelho 
et al. (2005) at the same concentrations. However, in this 
study, in animals that received a concentration of 4% 
CLA on food intake during the experiment, an aggressive 
behavior and at the end of the experiment, clinical signs 
of malnutrition as a change of coat and apathy were 
observed.  
When Sprague-Dawley mice were fed with a high-
hydrogenated soybean oil food with conjugated linoleic 
acid at 1.5, 3.0 and 5.0%, they did not show different diet 
intake, weight gain and feed efficiency, when compared 
with the control group after six weeks of experimentation 
(Choi et al., 2004; Akahoshi et al., 2004; Bissonauth et 
al., 2006; Purushotham et al., 2007). 
Wistar adult mice fed with food added with 1.5% CLA 
during three weeks did not show different diet intake, 
weight gain and feed efficiency when compared with the 
control group (Purushotham et al., 2007). Bissonauth et 
al. (2006) did not find any difference in diet intake and 
weight gain, neither in mice that received separately 
trans-10 and cis-12 CLA isomers and cis-9 and trans-
11CLA isomers nor in the control group that received 
linoleic acid.  
Santos-Zago et al. (2011) evaluated the effects of the 
consumption of two commercial conjugated linoleic acid 
(CLA) mixtures on lipid content and liver histology of 
healthy rats. The concentration of CLA was 2% of feed 
consumption, and the animals were daily supplemented 
for 42 days. The results of total liver lipid contents did not 
show significant differences between the groups. 
Regarding the hepatic histology, it was observed that 
although fat globules were visibly present in higher 
numbers and bigger size in the CLA groups, the organ 
histology was considered normal since both cytoplasm 
and organelles showed integrity.  
Among the methods of cytotoxicity investigation in 
genetic level and in vivo experiment, micronucleus test is 
performed on bone marrow and has been widely used 
and accepted by regulatory agencies and scientific 
community. This test detects genomic changes and/or 
influences in mitosis; in which micronucleus indicates 
irreversible loss in DNA.  Although genetic toxicity is not a 
measure of carcinogenicity, its frequency is associated 
with the development of cancer, therefore this is a good 
correlation between the high frequency of micronucleus 
and the appearance of tumors in mice and humans (Jena 
et al., 2002). 
In our study, the frequency of micronucleus found in 
positive control group was higher than that in negative 
control group, proving the efficiency of micronucleus test 
in this research. In the same way, damage-inducing 
agent, CP, was shown to be effective in inducing the 
chromosomal damage from immature erythrocytes 
(PCEs). 




CLA did not show mutagenic effect at any of the 
concentrations studied (2 and 4%). The frequency of 
MNPCE from the groups that received CLA was not 
different from that of the negative control group (safflower 
oil). Antimutagenic activity was observed at the two 
concentrations (2 and 4%), when compared to the control 
group that received CP intraperitoneal administration. 
CLA played a role in tumor growth and tumor 
development in different levels (initiation, promotion, 
progression and metastasis) by the decrease and 
retention of cellular multiplication. CLA has also acted in 
increasing programmed cellular death (apoptosis) and 
necrosis. Complementing this, CLA shows activity on 
immune system, as well as on the reduction of body fat 
accumulation, in which it indirectly influences the tumor 
appearance and improves cachexia (Field and Schley, 
2004; Pariza et al., 1999).  
In addition to its antimutagenic activity, CLA shows a 
protective activity, because the groups fed with CLA had 
a decreased MNPCEs number compared to the positive 
control group. The group that received intraperitoneal 
physiological solution of 0.9% showed decreased 
MNPCEs number. 
Similar results regarding anticarcinogenic/protective 
effect of CLA were obtained by Ip et al. (1991). Female 
mice fed with 10 mg of 7.12 dimethylbenzanthracene 
(carcinogenesis-inducing substance) had inhibition of 32, 
56 and 60% on mammary tumor rate when fed with 0.5, 
1.0 and 1.5% of CLA, respectively. This CLA supplement 
was started two weeks before administration of 
carcinogenic agent and kept receiving until the end of the 
experimentation. This research observed that c-9,  and t-
11 CLA could be the most active isomer against 
carcinogenesis inhibition, as it was the major compound 
present in the mixture.  
After this, lp et al. (1994) fed female mice with 
increased amounts of CLA (0.05, 0.1, 0.25, or 0.5%) 
during two weeks before administration of 5 mg of 7,12 
dimethylbenzanthracene. After 36 weeks of supple-
mentation, a dose-dependent reduction in the incidence 
and mammary tumor size were observed, proving a good 
biological activity of CLA on carcinogenesis treatment. 
Although “in vitro” results and animal experiments had 
showed beneficial effects using CLA in this kind of 
cancer, studies with women have not proved this 
association (Voorrips et al., 2002; Larsson et al., 2009). 
Research with gastrointestinal and colon tumor was done 
specially  by ‘in vitro’ assays and animal experiments 
(Palombo et al., 2002; Cohen et al., 2003; Ochoa et al., 
2004; Bhattacharya et al., 2006; Song et al., 2006). In 
one of the rare researches with humans, Larsson et al. 
(2005) suggested that the intake of high-CLA milk 
products decreases rectum cancer in 13% and colon 
cancer in 34%. Kuniyasu et al. (2006) found peritoneal 
metastasis inhibition of gastrointestinal cancer in 
humans. 
 Therefore, although more evidences are needed,  CLA  




has shown some effects on carcinogenesis in different 
tissues; however, the mechanisms involved could vary 
case by case: lipid peroxidation, fatty acid composition of 
tissue, eicosanoid metabolism, genetic expression, cell 
cycle regulation cell proliferation and apoptosis could play 





In this study, the supplementation of CLA at 2 and 4% on 
the diet of Swiss albino male mice showed antimutagenic 
effects, as assessed by micronucleous assay. No 
mutagenic effects to chemically induced DNA damage 
were observed. It is noteworthy that the mice that 
received 4% of CLA on feed intake showed clinical signs 
of malnutrition. Considering these results, further studies 
should be made to elucidate the mechanisms of how CLA 
has such effects, mainly regarding the clinical signs of 
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